Evidence map›Paper›PMID 36868731›Full record

ReviewAdvances in kidney disease and health2023

Breaking the Cycle of Recurrent Calcium Stone Disease.

Deepa A Malieckal, Calyani Ganesan, Denisse Arellano Mendez, Alan C Pao

Open access · greenAbstract readReview
In one paragraph

Review in Advances in kidney disease and health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Clinical features ofFrontiers in cellular and infection microbiology · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Deepa A MalieckalDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Kidney Diseases and Hypertension, Department of Medicine, Great Neck, NY.
Calyani GanesanStanford University School of Medicine, Division of Nephrology, Department of Medicine, Palo Alto, CA.
Denisse Arellano MendezMexican Social Security Institute, Division of Nephrology, Department of Internal Medicine, Guadalajara, Jalisco, Mexico.
Alan C PaoStanford University School of Medicine, Division of Nephrology, Department of Medicine, Palo Alto, CA; Veterans Affairs Palo Alto Health Care System, Medical Service, Division of Nephrology, Palo Alto, CA; Stanford University School of Medicine, Department of Urology, Palo Alto, CA. Electronic address: paoman@stanford.edu.
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell · USMexican Social Security Institute · MXStanford University · USVA Palo Alto Health Care System · US

Funding

Bone Health in Patients with Urinary Stone DiseaseK23DK128651 · NIDDK · STANFORD UNIVERSITY · PI Calyani Ganesan · 2022 to 2026
$964k
Defining Optimal Care for Urinary Stone Disease in the Veterans Health AdministrationI01HX003091 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI LEPPERT, JOHN THOMAS, PAO, ALAN C · 2020 to 2025
–
HSRD VA I01 HX003091NIDDK NIH HHS K23 DK128651
6 · The paper itself

Abstract

Calcium stones are common and recurrent in nature, yet few therapeutic tools are available for secondary prevention. Personalized approaches for stone prevention have been informed by 24-hour urine testing to guide dietary and medical interventions. However, current evidence is conflicting about whether an approach guided by 24-hour urine testing is more effective than a generic one. The available medications for stone prevention, namely thiazide diuretics, alkali, and allopurinol, are not always prescribed consistently, dosed correctly, or tolerated well by patients. New treatments on the horizon hold the promise of preventing calcium oxalate stones by degrading oxalate in the gut, reprogramming the gut microbiome to reduce oxalate absorption, or knocking down expression of enzymes involved in hepatic oxalate production. New treatments are also needed to target Randall's plaque, the root cause of calcium stone formation.

Indexed as

Body FluidsCalciumAlkaliesAllopurinolChronic DiseaseHumansOxalatesAlkaliesAllopurinolCalciumOxalates

Identifiers

PMID36868731
PMCPMC9993408
OpenAlexW4322734271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.